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Abstract
Levosimendan, the active enantiomer of simendan, is a calcium 
sensitizer developed for treatment of decompensated heart failure, 
exerts its effects independently of the beta adrenergic receptor and 
seems beneficial in cases of severe, intractable heart failure. Levo-
simendan is usually administered as 24-h infusion, with or without 
a loading dose, but dosing needs adjustment in patients with se-
vere liver or renal dysfunction. Despite several promising reports, 
the role of levosimendan in critical illness has not been thoroughly 
evaluated. Available evidence suggests that levosimendan is a safe 
treatment option in critically ill patients and may reduce mortality 
from cardiac failure. However, data from well-designed random-
ized controlled trials in critically ill patients are needed to validate 
or refute these preliminary conclusions. This literature review is an 
attempt to synthesize available evidence on the role and possible 
benefits of levosimendan in critically ill patients with severe heart 
failure.
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Introduction
Circulatory shock and peripheral hypo-perfusion are life-
threatening manifestations of critical illness and are asso-
ciated with high mortality [1]. Fluid administration serves 
as first-line therapy, but is often insufficient to improve pa-
tient’s condition, whereas beta-adrenergic agents increase 
cardiac output (CO) and organ perfusion through inotropic 
and chronotropic effects. Dobutamine, a beta-adrenergic 
agent commonly used in severe heart failure, increases CO, 
but also increases myocardial oxygen consumption, thereby 
increasing the risk of myocardial ischemia and ventricular 
dysfunction. Consequently, there are significant concerns re-
garding the balance of benefit vs. harm with dobutamine use 
in critically ill patients, and a recent systematic review sug-
gests that dobutamine may increase mortality [2].
Levosimendan, the active enantiomer of simendan, is a 
calcium sensitizer that was developed for treatment of de-
compensated heart failure (DHF). Unlike other inotropic 
agents, levosimendan enhances myocardial contractility 
without increasing myocardial oxygen consumption, and its 
primary actions are independent of interactions with adren-
ergic receptors. Compared to beta-adrenergic agents, pre-
sumed advantages of levosimendan include its combined 
inotropic and vasodilation (inodilator) effect, efficacy on pa-
tients receiving beta-blockers and minimal effects on heart 
rate. Although levosimendan has been endorsed by the Eu-
ropean Society of Cardiology for patients with acutely de-
compensated severe chronic heart failure [3], and a recent 
meta-analysis showed that levosimendan reduces mortality 
in critically ill patients [4], levosimendan is not widely used 
in intensive care units (ICUs). The aim of this review is to 
summarize and evaluate current evidence on the role of levo-
simendan in critically ill patients.
Levosimendan: Mechanism of Action
Levosimendan is a calcium sensitizer and exerts its inotropic 
effect principally via binding to the Ca++ saturated troponin 
C of myocardial thin filament. This action results in stabili-
zation of the Ca-bound conformation of troponin, thereby 
prolonging the actin-myosin interaction without altering 
cross-bridge cycling [5]. Although levosimendan inhibits 
phosphodiesterase III, its inotropic effect seems to depend 
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almost entirely on its calcium sensitizing properties [6]. 
Consequently, in contrast to other inotropic agents, levosi-
mendan does not increase calcium flux into the cell, and this 
could explain why levosimendan does not worsen myocardi-
al diastolic dysfunction, and may actually improve diastolic 
function [7]. Interestingly, despite improved cardiac perfor-
mance, levosimendan does not increase myocardial oxygen 
consumption and may increase myocardial oxygen supply 
through coronary vasodilation [8, 9].
Levosimendan causes vasodilation through its effect 
on K+ channels: it opens the K+ channels causing smooth 
muscle membrane hyperpolarization, thereby inhibiting cal-
cium channels and promoting vasodilation [10]. However, 
because the vasodilator effect of levosimendan is observed 
at plasma concentrations higher than those needed for posi-
tive inotropic effects [11], its clinical significance is unclear. 
Levosimendan also induces vasodilation in other organs, 
including the myocardium, gastric mucosa [12], lungs [13], 
small intestine, liver and renal medulla [14]. As a result, or-
gan perfusion is improved despite a small reduction of mean 
arterial pressure [9]. However, the clinical significance of 
levosimendan-related vasodilation has not been evaluated in 
critically ill patients, because studies evaluating levosimen-
dan safety usually exclude patients with severe hypotension 
(systolic blood pressure (SBP) < 90 mmHg) (Table 1). The 
clinical consequences of levosimendan-related vasodilation 
should be evaluated taking in consideration concurrent im-
provement in cardiac performance.
In addition to its inotropic and vasodilator effects, levo-
simendan has several other important effects, including anti-
inflammatory effect [15, 16] and anti-apoptotic effects [15]. 
Levosimendan decreases pro-inflammatory cytokine produc-
tion by diminishing transforming growth factor (TGF)-beta3 
and Smad1, Smad2 and Smad3 expression [17]. In addition, 
simendans downregulate NF-kappaB-dependent transcrip-
tion and decrease inducible NO synthase (iNOS) promoter 




Studies in healthy volunteers show that levosimendan phar-
macokinetics are linear to the dose: the area under the plas-
ma concentration-time curve (AUC) increases linearly and 
correlates with dose [19]. Levosimendan is 97-98% bound 
to plasma protein (mainly albumin) [20], has a small vol-
ume of distribution and its elimination from plasma is fast, 
with half-life being about 1 h [20]. Levosimendan is almost 
entirely metabolized by the liver before being eliminated by 
conjugation with glutathione, forming N-acetylated cysteine 
or cysteine-glycine. N-acetylated cysteine is excreted via the 
biliary route to the intestine, and is then eliminated by the 
kidneys [21].
A small amount of levosimendan is eliminated un-
changed through diffusion in the intestine, where it is 
transformed by intestinal bacteria to OR-1855 [22]. Then, 
OR-1855 is absorbed and further acetylated by N-acetyl-
transferase (NAT2) to OR-1986, which has effects similar to 
the parent substance [23] and half-life 60 - 80 h [24]. Nearly 
50% of OR-1986 is eliminated unchanged into urine, and the 
remainder is eliminated via other metabolic routes, including 
conversion back to OR-1855 [25].
Based on pharmacokinetic properties, levosimendan ki-
netics are influenced by: 1) albumin levels, 2) gastrointesti-
nal function and intestinal bacterial flora, 3) liver function, 4) 
NAT2 activity and 5) renal function.
Levosimendan and albumin levels
Hypoalbuminemia [26] and gastrointestinal dysfunction [27] 
are common in ICU patients, but their effects on levosimen-
dan pharmacokinetics have not been studied. In a case re-
port, low dose (0.07 µg/kg/min) levosimendan was effective 
in a patient with hypoalbuminemia (albumin level 3.1 mg/
dL) [28]. In addition, two studies evaluating levosimendan 
on patients with low albumin levels due to chronic renal or 
liver failure showed that the mean unbound fraction of levo-
simendan did not differ compared to healthy people [29, 30]. 
However, albumin levels in these two studies were higher 
(3.8 g/dL ± 0.1 and 3.9 g/dL ± 0.1, respectively) compared 
to albumin levels commonly reported in critically ill ICU 
patients.
Levosimendan and liver dysfunction
Liver dysfunction is common in ICU patients, and use of 
standard liver function tests may not be sufficient for evalu-
ating liver function [31]. One small prospective study com-
paring levosimendan pharmacokinetics in 12 patients with 
Child-Pugh class B cirrhosis vs. 12 healthy subjects showed 
that OR-1896 elimination time was longer in cirrhosis pa-
tients [29]; however, this study did not include critically ill 
patients or patients with heart failure. Unfortunately, patients 
with liver dysfunction were excluded from two multi-center 
studies evaluating levosimendan safety [32, 33]; therefore 
data on levosimendan safety in patients with liver disease are 
very limited, and more work is needed in this area. Currently 
available data on the safety of levosimendan in critically ill 
patients are summarized in Table 1.
 
Levosimendan and renal dysfunction
Acute renal failure is common in critically ill patients, and 
may affect the pharmacokinetics of levosimendan and its 
metabolites (OR-1896), due to reduced excretion. Levosi-
mendan is not eliminated by hemodialysis, but levosimendan 
metabolites are dialyzable, yet clearance through dialysis is 
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very slow (approximately 100 mL/min), and therefore short 
hemodialysis sessions may not have important effects [30]. 
An open label study on 12 patients with severe chronic renal 
failure and 13 patients with end-stage renal disease (ESRD) 
undergoing hemodialysis showed that, compared to healthy 
individuals, plasma half-life of levosimendan metabolites is 
prolonged by 50%, while the AUC and peak plasma con-
centrations are approximately twice as high in patients with 
severe renal dysfunction and those requiring hemodialysis 
[30]. However, we could not find studies evaluating levosi-
mendan pharmacokinetics in patients with severe renal dys-
function in the setting of critical illness.
In conclusion, our literature review shows that levosi-
mendan pharmacokinetics have not been well evaluated in 
critically ill patients, therefore more studies are needed to 
clarify this important issue.
Levosimendan Dose
  
A wide range of levosimendan doses has been reported in 
critically ill patients (Table 1), with doses differing signifi-
cantly between studies (bolus 0 - 24 µg/kg, continuous infu-
sion 0.05 - 0.2 µg/kg/min) [4]. The hemodynamic effects of 
levosimendan seem to be dose-dependent [23], but are also 
influenced by severity of heart failure. A multi-center (35 
centers) open label observational study in Brazil included 
182 patients with DHF and left ventricular ejection fraction 
(LVEF) < 35% and the primary end point was hospital dis-
charge without need for inotropic support after levosimen-
dan infusion. One hundred and thirty-nine of 182 patients 
(76.4%) met the primary end point and were classified as 
responders, and hospital mortality was 14.8% (27 patients). 
In this study, 25 of 30 patients receiving beta-blockers re-
sponded well to levosimendan. In contrast, in the subset of 
71 patients who had received beta-agonist inotropes for 48 
h and had failed to improve, only 39 of 71 patients (56%) 
responded, thereby suggesting that patients with more severe 
heart dysfunction respond less favorably to levosimendan 
[34].
Several studies have evaluated levosimendan safety in 
patients with acute heart failure or decompensated chronic 
heart failure. Two studies evaluated levosimendan safety, 
with dose titrated based on tolerance and/or clinical effects 
[33, 35]. The RUSSLAN study, a randomized controlled trial 
(RCT) on 504 patients with left ventricular failure after acute 
myocardial infarction (MI) evaluated different levosimendan 
doses (bolus 6, 12 and 24 μg/kg, continuous infusion 0.1 - 
0.2 μg/kg/h for 6 h) vs. placebo and showed higher frequen-
cy of hypotension and/or ischemia in the highest dose group, 
Table 1. Studies Evaluating the Safety of Levosimendan in Critically Ill Patients
Study Dose bolus Dose infusion Duration Major adverse effects
Aidonidis et al. Cardiol 
Res Pract. 2011 [35]
0 0.05 - 0.2 µg/kg/min 72 h No discontinuations due to 
adverse effects, two patients 
died of advanced heart 
failure. 
Follath et al. Lancet. 
2002 [38]
24 µg/kg 0.1 µg/kg/min 24 h Hypotension, headache, 
hypokalemia
Kivikko et al. J Clin 
Pharmacol. 2002 [37]
0.05 - 0.1 µg/kg/min 7 days No major adverse effects, no 
premature discontinuations
Moiseyev et al. Eur 
Heart J. 2002 [32]
6, 12, 24 µg/kg 0.1 - 0.4 µg/kg/min 6 h Hypotension, myocardial 
rupture, headache, sinus 
tachycardia
Poelzl et al. Herz. 2008 
[75]
6 - 12 µg/kg 0.07 - 0.2 µg/kg/min 24 h Not reported
Silva-Cardoso et al. Rev 
Port Cardiol. 2009 [33]
12 µg/kg 0.05 - 0.2 µg/kg/min 24 h Hypotension, hypokalemia
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and significantly lower mortality in all levosimendan groups 
compared to placebo [32]. Interestingly, these studies did not 
report adverse effects after the bolus doses.
Most published studies evaluate levosimendan admin-
istration for 24 h and show rapid initial hemodynamic im-
provement that persists after levosimendan discontinuation 
[36]. In addition, one prospective study on 70 patients with 
decompensated chronic heart failure evaluated prolonged 
(up to 72 h) levosimendan infusion without a loading dose 
and showed significant reduction of brain natriuretic peptide 
(BNP) levels at 48 h and 72 h without major complications 
[35]. Similarly, a prospective non-randomized study on 24 
patients with New York Heart Association (NYHA) III-IV 
heart failure evaluated a 7-day levosimendan infusion at 
0.05 μg/kg/min (12 patients) or 0.1 μg/kg/min (12 patients) 
and showed that prolonged levosimendan infusion was well 
tolerated without premature discontinuations, but adverse 
effects included prolonged increase in heart rate and minor 
decrease in blood pressure [37]. However, the benefits, if 
any, of prolonged (> 24 h) levosimendan administration vs. 
conventional 24 h infusions have not been evaluated.
Levosimendan vs. Other Inotropes
Levosimendan vs. dobutamine
Levosimendan was compared to dobutamine in a multi-cen-
ter RCT (LIDO study) on 213 patients with low CO heart fail-
ure (acute or decompensated chronic heart failure) requiring 
intravenous inotropes [38]. In this study, levosimendan was 
more effective than dobutamine in producing hemodynam-
ic improvement: more patients in the levosimendan group 
(28% vs. 15%; P = 0.02) had CO increase by at least 30% 
and pulmonary-capillary wedge pressure decrease by 25% 
compared to baseline at 24 h. It is possible that levosimen-
dan is more effective than dobutamine because it improves 
left ventricular diastolic function parallel with improvement 
of systolic function [39]. In general, levosimendan seems 
superior to dobutamine with regards to improving regional 
and systemic perfusion, possibly because of its greater va-
sodilator effect. An RCT on 40 patients with septic shock 
compared a 24 h infusion of levosimendan 0.2 μg/kg/min 
vs. dobutamine 5 μg/kg/min: dobutamine was comparable to 
levosimendan with regards to reduction of mean pulmonary 
artery pressure, right atrial pressure and pulmonary artery 
occlusion pressure, and increase of stroke index and cardiac 
index (CI), but regional and systemic perfusion were signifi-
cantly higher in the levosimendan group [40].
Unfortunately, it is not clear whether the observed he-
modynamic advantages of levosimendan over dobutamine 
result in improved survival. A secondary analysis of data 
from the LIDO study showed that patients treated with levo-
simendan had higher 180-day survival. In contrast, the SUR-
VIVE study, a large (1,327 patients) multi-center (75 cen-
ters) international (9 countries) RCT showed that all-cause 
mortality at 6 months was 26% in the levosimendan group 
vs. 28% in the dobutamine group, and the difference was not 
significant [41]. In contrast, secondary analysis of the SUR-
VIVE study data showed lower mortality with levosimendan 
in patients with decompensated chronic heart failure and in 
patients previously treated with beta-blockers [42]. How-
ever, levosimendan does not seem superior to dobutamine 
with regards to survival in patients with acute heart failure 
without history of chronic heart failure [43].
Levosimendan seems to have synergistic hemodynamic 
effects with dobutamine. A prospective study evaluated the 
effects of combining levosimendan with dobutamine on 18 
patients hospitalized for NYHA class IV heart failure refrac-
tory to continuous 24-h infusion of dobutamine 10 μg/kg/
min and furosemide 10 mg/h. Addition of levosimendan (6 
μg/kg bolus followed by infusion at 0.2 μg/kg/min for 24 h) 
was well tolerated, increased CI by > 40% in 14 of 18 pa-
tients at the end of the combined infusion, and the observed 
improvement of CI persisted 1 week later. This study con-
cluded that the levosimendan/dobutamine combination was 
more effective than dobutamine alone, without additional 
adverse effects in refractory heart failure [44]. These results 
suggest that levosimendan is probably not meant to replace 
dobutamine, but is a useful adjunct therapy in patients with 
heart failure refractory to dobutamine.
Levosimendan vs. phosphodiesterase inhibitors
Experimental data suggest that levosimendan and phospho-
diesterase inhibitors have similar efficacy in improving sys-
tolic cardiac function [45] and may exert similar cardiopro-
tective effects [46]. However, levosimendan also improves 
diastolic cardiac function, whereas milrinone does not [46, 
47].
An RCT on 30 patients with LVEF < 30% scheduled for 
elective cardiac surgery compared milrinone 0.5 μg/kg/min 
vs. levosimendan 0.1 μg/kg/min starting after the release of 
the aortic cross-clamp, while all patients also received do-
butamine 5 μg/kg/min. In this study, patients in the levosi-
mendan group required lower doses of norepinephrine (P = 
0.007) had faster weaning from dobutamine, shorter dura-
tion of mechanical ventilation (P = 0.008) and no differences 
in adverse effects (hypotension, arrhythmia), ICU length of 
stay (LOS) or hospital LOS. With regards to mortality, there 
were three deaths in the milrinone vs. 0 deaths in the levo-
simendan group at 30 days, but this difference did not reach 
statistical significance [48].
Another RCT compared levosimendan (bolus 12 μg/kg 
over 10 min followed by infusion at 0.1 - 0.2 μg/kg/min for 
24 h) vs. milrinone (bolus 50 μg/kg over 10 min followed 
by infusion of 0.3 - 0.5 μg/kg/min for 24 h) on 30 patients 
with type II diabetes and low LVEF who developed low car-
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diac output syndrome (LCOS) after cardiopulmonary bypass 
(CPB) for elective coronary artery bypass graft (CABG) sur-
gery. This study showed significantly higher CI (P = 0.01) 
and mixed venous oxygen saturation (P < 0.001) and signifi-
cantly lower oxygen extraction ratio (P = 0.03), pulmonary 
capillary wedge pressure (PCWP) (P = 0.04) and systemic 
vascular resistance (SVR) (P = 0.01) in the levosimendan 
group compared to the milrinone group [49].
Levosimendan has also been compared to enoximone 
in an RCT on 32 patients with persistent cardiogenic shock 
(shock despite successful reperfusion therapy, administra-
tion of inotropes and fluids and support with intra-aortic 
balloon pump (IABP)) after acute MI. Levosimendan was 
given as 12 μg/kg over 10 min loading dose followed by 0.1 
μg/kg/min infusion for 50 min and 0.2 μg/kg/min infusion 
over 23 h, whereas enoximone was given as 0.5 μg/kg over 
30 min bolus followed by 2 - 10 μg/kg/min infusion titrated 
to hemodynamic response for a median of 5.1 days. In this 
study, although hemodynamic changes did not differ signifi-
cantly between the two groups, survival was higher in the 
levosimendan group (69% with levosimendan vs. 37% with 
enoximone, P = 0.023) [50].
Levosimendan in Critically Ill Patients
Levosimendan in cardiac surgery
Morbidity after cardiac surgery has increased in recent years 
and, despite improved cardioplegic protection, postoperative 
LCOS remains a problem, largely because cardiac surgery 
is increasingly utilized in older, higher risk patients. LCOS 
consists of transient ventricular dysfunction related to global 
myocardial ischemia and reperfusion injury, is also known as 
myocardial stunning and is associated with high morbidity 
and mortality. In one meta-analysis, cardiac surgery patients 
who received levosimendan perioperatively had lower mor-
tality compared to patients treated with placebo, dobutamine 
or milrinone (4.7% vs. 12.7%, P = 0.003), whereas another 
meta-analysis included 139 cardiac surgery patients from 
five RCTs and showed that levosimendan has cardioprotec-
tive effects, as evidenced by lower postoperative troponin 
levels in patients receiving levosimendan. However, these 
finding are based on relatively small number of patients, and 
need to be confirmed in larger studies [51, 52].
One RCT evaluating levosimendan (10 μg/kg loading 
dose followed by 0.1 μg/kg/min for 24 h) vs. dobutamine 
(starting at 5 μg/kg/min) as monotherapy in 137 patients with 
LCOS after elective CABG showed fewer complications and 
significantly lower mortality (9% vs. 25%, P < 0.05) in the 
levosimendan group [53].
Levosimendan for primary graft failure after heart trans-
plantation has been reported in two publications originating 
from the same center in Germany [54, 55]. Levosimendan 
was given as 24-h infusion at 0.1 μg/kg/min in 12 patients 
with primary graft failure, resulted in rapid improvement of 
heart function and 30 day survival was 92% [55].
Prophylactic levosimendan has also been evaluated in 
cardiac surgery: an RCT evaluated levosimendan use (bolus 
12 μg/kg followed by infusion at 0.2 μg/kg/min) immedi-
ately after induction of general anesthesia vs. placebo in 60 
patients with LVEF < 50% undergoing CABG surgery, and 
showed that a primary weaning from CPB was successful 
in 22 patients (73%) in the levosimendan group vs. 10 pa-
tients (33%, P = 0.002) in the placebo group [56]. Another 
prospective study in patients with LVEF < 35% undergoing 
cardiac surgery under CPB compared prophylactic levosi-
mendan (bolus 12 μg/kg followed by infusion at 0.1 μg/kg/
min for 24 h) starting after induction of anesthesia vs. IABP 
starting 16 - 18 h before surgery, and showed higher CI and 
lower troponin levels 6 h after surgery and significantly 
shorter ICU LOS in the levosimendan group [57].
Similarly, another RCT on 252 patients with LVEF < 
25% undergoing CABG under CPB, compared preoperative 
levosimendan (loading dose 10 μg/kg followed by infusion 
at 0.1 μg/kg/min for 23 h) vs. placebo and showed signifi-
cantly lower incidence of LCOS (7.1% vs. 20.8%, P < 0.05), 
lower requirement for IABP (6.3% vs. 30.4%, P < 0.05) and 
lower mortality (3.9% vs. 12.8%, P < 0.05) in the levosimen-
dan group [58]. Another small retrospective study compared 
10 high-risk cardiac surgery patients (Euroscore > 6) with 
severe left ventricle (LV) dysfunction who received prophy-
lactic levosimendan (bolus 24 μg/kg followed by infusion 
at 0.1 μg/kg/min for 24 h) with 12 historical controls and 
showed that patients who received levosimendan had higher 
CI, shorter hospital LOS and lower 30-day mortality com-
pared to patients who received dobutamine and milrinone 
[59].
Furthermore, an RCT on 106 patients undergoing elec-
tive CABG surgery evaluated levosimendan (24 μg/kg as 
slow IV bolus 10 min before CPB) vs. placebo and showed 
lower troponin values (P = 0.0001), reduced need for ino-
tropic support and significantly shorter duration of mechani-
cal ventilation and ICU LOS (P = 0.01) in the levosimendan 
group [60].
However, a retrospective matched-control study in pa-
tients with LVEF < 30% undergoing cardiac surgery con-
cluded that prophylactic levosimendan infusion starting be-
fore weaning from CPB resulted in significantly lower mean 
arterial pressure and need for higher doses of norepineph-
rine, without any benefit in CI, mixed venous oxygen satura-
tion, or 30-day mortality [61].
Although the inotropic and vasodilator effects of levosi-
mendan are a concern in patients with severe valve disease, 
particularly aortic stenosis [62], a recent report described 
successful preoperative levosimendan use in two adults with 
severe aortic stenosis [63], and a few studies have evaluated 
the use of levosimendan in heart valve surgery. A small RCT 
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from Finland on 24 patients undergoing aortic valve replace-
ment with or without CABG showed that patients who re-
ceived levosimendan at 0.2 μg/kg/min for 24 h starting after 
induction of anesthesia required more norepinephrine during 
surgery and less nitroprusside after surgery, but maintained 
their pre-CPB LVEF and avoided myocardial stunning [64]. 
Similarly, a large RCT from a different center in Finland 
evaluated levosimendan (24 μg/kg bolus over 30 min) start-
ing immediately after induction of anesthesia and continuing 
at 0.2 μg/kg/min for 24 h vs. placebo in 200 patients with 
normal preoperative cardiac function undergoing elective 
isolated valve or combined valve-CABG surgery [65]. This 
study showed reduced heart failure but increased need for 
vasopressors and no difference in 6-month mortality in the 
levosimendan group.
In conclusion, the optimal strategy for levosimendan 
administration (prophylactic vs. use in LCOS) in cardiac 
surgery is matter of discussion [66]. Early levosimendan ad-
ministration may be more effective [67], but the issue has not 
been resolved and deserves further evaluation.
Levosimendan in cardiogenic shock
Because levosimendan causes vasodilation, cardiogenic 
shock has been exclusion criterion in studies evaluating le-
vosimendan safety, and therefore levosimendan has not been 
adequately studied in cardiogenic shock. In the BELIEF 
study, hypotension (SBP < 90 mmHg) before levosimendan 
administration was a good predictor for absence of response 
to levosimendan treatment [34]. However, published data 
suggest that levosimendan is well tolerated in patients with 
cardiogenic shock after acute MI [68, 69] and its hemody-
namic effects are comparable to those of IABP [70], but the 
timing of levosimendan administration remains matter of 
controversy. One prospective observational study compared 
early (in the cardiac catheterization suite at the time of IABP 
initiation) vs. late (persistent cardiogenic shock despite suc-
cessful reperfusion therapy, IABP and optimized fluid ad-
ministration) levosimendan administration and showed no 
benefit in short term (< 30 days) or long term (> 30 days) 
mortality with early levosimendan administration [71]. Late 
levosimendan administration significantly increased CI 
without hemodynamic deterioration in patients with persis-
tent cardiogenic shock (no improvement of CI after reper-
fusion treatment, IABP, optimized fluid or dobutamine ad-
ministration) [72, 73], but hemodynamic improvement did 
not improve survival [72]. To this day, there are no RCTs 
evaluating levosimendan in cardiogenic shock secondary to 
acute MI.
Experimental data in dogs show that levosimendan im-
proves right ventricular function in load-induced acute right 
ventricular failure [74]. Three studies evaluating levosimen-
dan in cardiogenic shock due to bi-ventricular acute heart 
failure showed improved right ventricular function [75-77], 
presumably due to decreased pulmonary vascular resistance 
and improved right ventricular systolic function. Further-
more, the observed improvement of right ventricular systolic 
function (as measured with right ventricular cardiac power 
index (CPI)) was related to survival [77]. To this date, there 
are no studies evaluating levosimendan in cardiogenic shock 
secondary to isolated right heart failure.
Levosimendan could potentially be effective in other 
types of cardiogenic shock, such as in fulminant myocarditis 
[78], in patients with takotsubo cardiomyopathy [79, 80] and 
in cardiomyopathy after cardiac arrest, but there are no pro-
spective clinical trials evaluating the role of levosimendan in 
these settings.
Levosimendan in sepsis
Sepsis and septic shock have complex pathophysiology, in-
cluding cardiovascular dysfunction characterized by signs of 
distributive shock and of septic cardiomyopathy consisting 
of bi-ventricular myocardial contractility impairment and di-
astolic dysfunction. Available evidence suggests that cardiac 
failure in septic shock is not always corrected by vasoactive 
and inotropic agents or fluid therapy [81].
Experimental studies show that levosimendan improves 
systolic and diastolic myocardial function in sepsis, whereas 
clinical studies have shown that levosimendan improves car-
diac function in patients with septic shock. Consequently, le-
vosimendan could be a valuable adjunct (or replacement) in 
the treatment of sepsis-related myocardial dysfunction with 
catecholamines, but there are no guidelines for levosimen-
dan use in sepsis. A pilot RCT on 35 patients with septic 
shock and acute respiratory distress syndrome (ARDS), but 
without signs of right heart failure showed that continuous 
infusion of levosimendan (0.2 μg/kg/min for 24 h) decreased 
pulmonary resistance and improved right ventricular func-
tion (decreased telosystolic volume, increased EF) compared 
to placebo [82]. Yet, it is unclear whether the observed im-
provement of right ventricular function and reduction of 
pulmonary vascular resistance is due to direct levosimendan 
effect on the right ventricle or to improved LV function.
Levosimendan could also be effective in patients with 
sepsis-related myocardial dysfunction who do not respond 
to dobutamine: an RCT on 28 patients with septic shock and 
left ventricular dysfunction showed hemodynamic improve-
ment with levosimendan (0.2 μg/kg/min) even in patients 
who had not responded to dobutamine [83]. These results 
suggest that levosimendan could be an alternative option in 
cases where dobutamine is not effective, but this possible use 
needs further evaluation.
Levosimendan in renal dysfunction and renal failure
The long-term impact of levosimendan on renal function has 
not been well defined. An RCT on 40 patients with advanced 
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chronic heart failure listed for heart transplantation evaluat-
ed the effect of levosimendan on renal function, and showed 
that patients receiving levosimendan had lower serum creati-
nine and higher creatinine clearance 3 months after levosi-
mendan administration [84]. Other reports also suggest that 
levosimendan can have beneficial effects with regards to re-
nal function. An RCT by Bragadottir [85] compared postop-
erative infusion of levosimendan (loading 12 μg/kg followed 
by infusion at 0.1 μg/kg/min) vs. placebo in the cardiotho-
racic ICU on 30 patients who had cardiac surgery. In this 
study, levosimendan increased renal blood flow by 12% (P < 
0.05) and glomerular filtration rate by 21% (P < 0.05). Simi-
larly, an RCT by Hou et al compared a 24-h infusion of levo-
simendan vs. placebo in 66 patients with LVEF < 40% and 
DHF, and showed that levosimendan transiently improved 
renal dysfunction, and this improvement persisted for at least 
14 days [86]. A study by Yilmaz showed that, compared to 
dobutamine, levosimendan resulted in improved renal func-
tion in heart failure patients requiring inotropic therapy [76], 
and a case report of a 14-year-old patient suggested that le-
vosimendan is useful in cases of resistant acute heart failure 
with arterial hypertension and ESRD [87]. However, it is im-
portant to remember that levosimendan doses should be re-
duced when used for congestive heart failure in patients with 
severe renal insufficiency [30]. A recent consensus statement 
by 25 scientists from 15 European countries acknowledged 
that most reports on levosimendan use show improvement of 
renal function in heart failure, sepsis and cardiac surgery, but 
also voiced caution with interpretation of these findings due 
to variability in study design, and also because the largest 
heart failure study (REVIVE I and II) did not show improved 
renal function [88]. Clearly, although available data suggest 
that levosimendan can be useful in patients with renal dys-
function and heart failure, the role of levosimendan in this 
patient population needs further study.
Conclusion
Levosimendan is a positive inotropic agent with many po-
tential applications in critically ill patients. However, indica-
tions, contraindications and optimal use of levosimendan in 
the ICU have not been adequately evaluated. Although one 
meta-analysis and several clinical studies report positive re-
sults with use of levosimendan in critically ill patients, we 
believe that currently available evidence cannot support safe 
conclusions regarding the role of levosimendan in the ICU, 
and data from large, well-designed RCTs are needed to vali-
date these preliminary results.
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